慢性淋巴细胞白血病中 CD20 mRNA 和蛋白水平的定量分析提示存在转录后缺陷。

Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect.

机构信息

Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada.

出版信息

Leuk Res. 2010 Dec;34(12):1670-3. doi: 10.1016/j.leukres.2010.06.031. Epub 2010 Aug 2.

DOI:10.1016/j.leukres.2010.06.031

PMID:20674973

Abstract

Chronic lymphocytic leukemia is less effectively treated than other B cell malignancies with the anti-CD20 agent, rituximab, presumably due, at least in part, to low CD20 expression. CD20 expression is typically measured by flow cytometry, which may not be quantitative. This study was undertaken to measure total CD20 protein in CLL B cells using quantitative immunoblot analysis. The results demonstrated that total CD20 protein levels were consistently decreased by ∼60% in CLL B cells with low CD20 fluorescence staining. Surprisingly, real-time polymerase chain reaction analysis showed that CD20 mRNA levels were normal or close to normal, depending on the comparative B cell population, and did not correlate well with protein expression. We conclude that CD20 protein is substantially decreased in CLL due to a post-transcriptional defect.

摘要

慢性淋巴细胞白血病的治疗效果不如其他 B 细胞恶性肿瘤好，用抗 CD20 药物利妥昔单抗治疗也是如此，这可能至少部分是由于 CD20 表达水平低。CD20 的表达通常通过流式细胞术来测量，但这种方法可能不是定量的。本研究旨在使用定量免疫印迹分析来测量 CLL B 细胞中的总 CD20 蛋白。结果表明，低 CD20 荧光染色的 CLL B 细胞中总 CD20 蛋白水平持续下降约 60%。令人惊讶的是，实时聚合酶链反应分析显示，CD20 mRNA 水平正常或接近正常，具体取决于比较 B 细胞群体，与蛋白表达相关性不大。我们得出结论，由于转录后缺陷，CLL 中的 CD20 蛋白大量减少。